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Abstract
Background: Hypertension remains the leading risk factor for cardiovascular disease (CVD) worldwide, and its
impact in Brazil should be assessed in order to better address the issue. We aimed to describe trends in prevalence
and burden of disease attributable to high systolic blood pressure (HSBP) among Brazilians ≥ 25 years old according
to sex and federal units (FU) using the Global Burden of Disease (GBD) 2017 estimates.
Methods: We used the comparative risk assessment developed for the GBD study to estimate trends in attributable
deaths and disability-adjusted life-years (DALY), by sex, and FU for HSBP from 1990 to 2017. This study included 14
HSBP-outcome pairs. HSBP was defined as ≥ 140 mmHg for prevalence estimates, and a theoretical minimum risk
exposure level (TMREL) of 110–115 mmHg was considered for disease burden. We estimated the portion of deaths
and DALYs attributed to HSBP. We also explored the drivers of trends in HSBP burden, as well as the correlation
between disease burden and sociodemographic development index (SDI).
Results: In Brazil, the prevalence of HSBP is 18.9% (95% uncertainty intervals [UI] 18.5–19.3%), with an annual 0.4%
increase rate, while age-standardized death rates attributable to HSBP decreased from 189.2 (95%UI 168.5–209.2)
deaths to 104.8 (95%UI 94.9–114.4) deaths per 100,000 from 1990 to 2017. In spite of that, the total number of
deaths attributable to HSBP increased 53.4% and HSBP raised from 3rd to 1st position, as the leading risk factor for
deaths during the period. Regarding total DALYs, HSBP raised from 4th in 1990 to 2nd cause in 2017. The main
driver of change of HSBP burden is population aging. Across FUs, the reduction in the age-standardized death rates
attributable to HSBP correlated with higher SDI.
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Conclusions: While HSBP prevalence shows an increasing trend, age-standardized death and DALY rates are decreasing in
Brazil, probably as results of successful public policies for CVD secondary prevention and control, but suboptimal control of
its determinants. Reduction was more significant in FUs with higher SDI, suggesting that the effect of health policies was
heterogeneous. Moreover, HSBP has become the main risk factor for death in Brazil, mainly due to population aging.
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Background
Cardiovascular disease (CVD) is the major cause of mor-
bidity and mortality in developed countries, and the
same trend has been observed in Brazil since the epi-
demiological transition, in the 1960s [1]. Besides being
the leading cause of death and hospitalizations in the
country, CVD also poses a significant economic burden
[1]. Hypertension (HTN) is the most prevalent risk fac-
tor for CVD, affecting 32.3% of Brazilian adults [2, 3].
HTN is associated with ischemic heart disease and
stroke, the main causes of death in the country, and is
also a risk factor for heart failure, chronic kidney disease,
cognitive decline, and other diseases [4]. Thus, there is a
recognized strong association of HTN with many dis-
eases and early preventive and therapeutic interventions
are available. However, the asymptomatic nature of the
disease in most of its clinical course and the lack of
awareness about the condition are contributing factors
for its underdiagnosis, especially in early stages [1]. Pub-
lished estimates suggest that among hypertensive young
adults in the USA, less than 75% are aware of the diag-
nosis, only about 60% are adequately treated, and around
40% have adequate control [5]. Macinko et al. using data
from Brazil National Health Survey conducted in 2013
found that 89% of hypertensive patients had contact with
the health system in the past 2 years, but only 65% were
aware of their condition, and 33% had their BP under
control [6]. In a cohort of Brazilian civil servants, results
are similarly suboptimal, with 80.2% awareness among
hypertensives and 53% with adequate control [7].
Most of the basic pharmacological arsenal for HTN is
freely available in the Brazilian Public Health System
(Sistema Único de Saúde (SUS)), and national programs,
especially in primary care, have been implemented to
improve population awareness, early diagnosis, and ad-
herence to HTN treatment [8]. However, the scope of
these initiatives is still heterogeneous, and their practical
results have not yet been adequately measured. Consist-
ent epidemiological data are needed for the development
of health policies in order to reduce the impact of HTN
in Brazil.
The primary objective of the present study is to
analyze the prevalence of and the burden of diseases at-
tributable to high systolic blood pressure (HSBP) among
Brazilians according to sex and federal units (FU)
between 1990 and 2017, based on the estimates of the
Global Burden of Disease 2017 study (GBD 2017). Add-
itionally, we aimed to assess the correlation between
HSBP burden and socioeconomic development.
Methods
The Global Burden of Disease study
The GBD study is a multinational research collaboration
with the objective to produce consistent estimates of
health problems related to more than 328 diseases and
injuries in 195 countries and territories. A wide range of
data sources (national surveillance—such as the National
Health Survey, which measured blood pressure measure-
ments in the Brazilian adult population in 2013 [3]—
vital records and verbal autopsy, published and unpub-
lished disease registries, and published scientific litera-
ture) and methods were employed to produce specific
results by age and sex for the years 1990–2017, updated
annually for the entire time series. Estimation techniques
imply that Brazilian data, when available, is weighted
much more heavily than data from other geographies
and primarily drives the estimates. Methods from the
GBD 2017 study have been described in detail [9–11].
Methodological specificities of the GBD estimates in
Brazil have been previously reported, for the GBD 2015
study [12]. Methods specific to the GBD estimation of
HSBP and its burden have been reported for the GBD
2015 study as well [13].
Methodology for the evaluation of risk factors in the GBD
study
GBD’s Comparative Risk Analysis (CRA) is a compre-
hensive and comparable approach to individual quantifi-
cation of risk factors, a tool for synthesizing risk
evidence and risk-outcome associations. The conceptual
CRA framework establishes a causal network of hier-
archically organized (5 hierarchical levels) risks or causes
that contribute to health outcomes, as well as the attrib-
utable burden by age, gender, cause, and location, allow-
ing the quantification of risks or causes at any level of
the structure. The relationship between risk exposures
and socio-demographic development, as measured by
the Sociodemographic Index (SDI), provides additional
data on the magnitude of this social interaction [9].
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The GBD CRA structure is based on the premise that
the risk caused by a given exposure starts at a certain
level and then increases as the exposure rises above that
level. Four components feed into the calculations to esti-
mate the burden attributable to a given risk-outcome
pair: (1) the estimate of the measured burden metric for
a cause (i.e., number of deaths, years of life lost (YLLs),
years lived with disability (YLDs), or disability-adjusted
life-years (DALYs) [10, 11, 14]), (2) the exposure levels
for the risk factor, (3) the counterfactual level of risk fac-
tor exposure or theoretical minimum risk exposure level
(TMREL), and (4) the relative risk of the outcome, re-
lated to the TMREL. For a given risk-outcome pair, the
attributable DALYs as the total DALYs for outcome
multiplied by the Population-Attributable Fraction
(PAF) at the risk-outcome pair for a given age, sex, loca-
tion, and year was estimated. The same applies to the es-
timation of attributable deaths, YLLs, and YLDs. The
PAF is defined as the proportion of burden due to a
cause that occurred because of exposure to a given risk
factor—considering the counterfactual level of TMREL,
in this case for HSBP [9].
For the production of estimates for risk factors, central
estimates (means) with 95% uncertainty intervals (95%
UIs) were reported. To ensure that UIs capture the uncer-
tainty of all relevant sources (exposures, relative risks
(RR), TMRELs, and disease burden estimates), uncertainty
was propagated through the analysis. When reported, the
percent change estimates were calculated from the central
estimates for the time points being compared [9]: the 95%
UI was calculated by performing a percent change calcula-
tion of the full set of 1000 draws in order to propagate un-
certainty. The percent change of the means was then
taken to report the mean percent change, and the 95% UI
were taken from the draw level calculation.
More detailed methodological information is available
in the GBD 2017 publication on risk factor-related bur-
den of disease [9].
Estimates for high systolic blood pressure
The GBD study estimates for HSBP are produced for in-
dividuals ≥ 25 years old. For GBD 2017, 2 new outcomes
were added for HSBP: subarachnoid hemorrhage and
calcific aortic valve disease, totaling 14 related outcomes
(with RRs estimated from published analyses of multiple
studies, including a large cohort pooling project [15]):
(a) ischemic heart disease, (b) ischemic stroke, (c)
hemorrhagic stroke, (d) hypertensive heart disease, (e)
cardiomyopathy, (f) atrial fibrillation, (g) aortic
aneurysm, (h) rheumatic heart disease, (i) peripheral vas-
cular disease, (j) endocarditis, (k) chronic kidney disease,
(l) subarachnoid hemorrhage, (m) calcific aortic valve
disease, and (n) other cardiovascular diseases (not listed
above). Endocarditis is included due to its association
with HSBP in large cohort studies, possibly through the
effect of blood pressure on endocarditis-related heart
failure. For the outcomes, not only conditions directly
resulting from, but also those aggravated by HSBP levels
were considered [9, 13]. The aggregate result included
death and morbidity. For each outcome, the age- and
sex-specific RRs associated with a measured systolic
blood pressure were estimated using the DisMod meta-
regression tool, considering a TMREL of 110–115
mmHg [9, 13]. For this study, prevalence of HSBP con-
sidered exclusively the presence of measured SBP ≥ 140
mmHg, derived from the continuous GBD estimation of
SBP, regardless of the diastolic blood pressure (DBP) or
the use of anti-hypertensive drugs.
This analysis was divided into 5 components: (1) dis-
tribution of HSBP (prevalence) by age, sex, and location;
(2) RRs of the 14 outcomes; (3) determining specific
PAF for selected outcomes; (4) estimation of attributable
deaths and DALYs, stratified by Brazilian federal units,
sex, and group of years; and (5) drivers of trends for
morbidity and mortality [9–11].
Metrics of disease burden
The DALYs combine information regarding premature
death (YLLs) and disability caused by the condition
(YLDs) to provide a summary measure of the healthy
years lost due to the condition. The YLLs were calculated
by multiplying the deaths observed at each specific age in
a certain year by the reference age-specific life expectancy
estimated from life table methods. The YLDs were calcu-
lated by multiplying health states resulting from sequelae
of diseases caused by HSBP (in number of cases/year) by a
health-state-specific disability weight representing a de-
gree of lost functional capacity. The process of estimating
the burden of the disability has been previously described
in detail [10, 11, 14, 16]. The burdens of disability were
determined via home interviews in several countries, in
which participants were asked to choose between lay de-
scriptions of different health states. For the aggregate of
multiple health outcomes attributable to HSBP, adjust-
ment of estimates was performed to account for comor-
bidity, simulating 40,000 individuals in each age-sex-
country-year stratum exposed to the independent likeli-
hood of developing each condition, based on disease
prevalence, with 95% UI reported for each estimate [11].
Combining disability weights for each simulated individ-
ual, this adjustment adds correlations between coexisting
diseases to the model. Age-standardization was obtained
via the direct method, applying a global age structure [14,
16] (Supplement 1).
Drivers of trends
A decomposition analysis of changes in DALYs—a
modification of the 3-factor Das Gupta decomposition
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[9, 17]—was undertaken over the time period into 4
main components, due to changes in (1) population
growth, (2) population age structure, (3) risk exposure,
and (4) all other factors not included in the analysis, the
latter termed as the risk-deleted death and DALY rates.
Risk-deleted rates refer to age-standardized death and
DALY rates expected if all risk factors included in GBD
2017 were removed, estimated as age-standardized
DALY rates multiplied by one minus the PAF for the set
of risks. The decomposition analysis was performed for
each 5-year time period. The contribution of changes in
exposure to the individual risks was scaled to the all-risk
effect at the most detailed outcome level [10, 11].
Sociodemographic index (SDI)
The SDI—weighted geometric mean of per capita in-
come, schooling level, and fertility rate under the age of
25—from 1990 to 2017 was used as an estimate of the
socioeconomic level of each geographic location, aiming
to assess its association with the burden of HTN as a
function of the global epidemiological transition [18].
Theoretically, SDI ranges from 0 (lowest) to 1 (highest)
and, among countries included in GBD, varies from 0.19
(South Sudan) to 0.94 (Luxembourg).
This study is based on the GBD 2017 data and analytic
methods, as described previously in detail [9–11], and
on the methodology for data collection and adjustment
techniques, as described above. Data were analyzed for
the period from 1990 to 2017. All analyses were strati-
fied by sex and presented as absolute and age-
standardized estimates for the different FUs of the Bra-
zilian territory, in addition to a comparison of the esti-
mates from Brazil with those of the BRICS countries
(Brazil, Russia, India, China, and South Africa) and other
countries with universal healthcare (Canada and Eng-
land), for a better global contextualization of the esti-
mates. Some analyses were further stratified by SDI.
Ethical considerations
The GBD study was approved by the Institutional Re-
view Board of the University of Washington. There was
no need to submit to this research to the local Institu-
tional Review Boards, as the study was conducted in a
public domain secondary database, without nominal
identification, in accordance with Decree No. 7,724, May
16, 2012, and Resolution 510, of April 7, 2016. The GBD
Brazil study was approved by the Institutional Review
Board of the Universidade Federal de Minas Gerais,
under the protocol CAAE – 62803316.7.0000.5149.
Results
Prevalence of HSBP
Table 1 shows the age-standardized prevalence of HSBP
in Brazil, which increased from 1990 to 2017, from
16.9% (95%UI 16.5 to 17.3%) to 18.9% (95%UI 18.5 to
19.3%), being higher in men than women along the
whole period (Fig. 1a). Although its annualized rate of
change is still positive 0.4% (95% UI 0.3 to 0.5%), Fig. 1a
reveals that the rise in prevalence rates are declining
across the years. If the rates evaluated are not standard-
ized for age, the increase in prevalence is higher (Table 1
and Fig. 1b), due to population aging. Crude and age-
standardized prevalence rates and annualized percent
change for each federal unit, for both sexes and stratified
by sex, are shown in Table 1.
Mortality and morbidity attributed to HSBP
Figure 2a shows that HSBP is the leading risk factor for
the total number of deaths in Brazil and has risen from
3rd in 1990 to 1st position in 2017. During the period,
the total number of deaths attributable to HSBP in-
creased 53.4% (95% UI 50.0 to 57.4%) (Table 2), ac-
counting for 150,250 (95% UI 135,714 to 164,122)
deaths in 1990 and 230,454 (95% UI 209,698 to 251,499)
in 2017. Regarding DALY, HSBP has also gained import-
ance rising from 4th to 2nd position from 1990 to
2017—only behind smoking (Fig. 2b). The leading role
of HSBP as a risk factor for death is for both sexes and
results from deaths due to cardiovascular and chronic
kidney diseases (Fig. 3).
When evaluating the age-standardized death rate at-
tributable to HSBP in Brazil, it has fallen 44.6% (95% UI
42.9 to 45.9%), from 189.2 (95% UI 168.5 to 209.2)
deaths to 104.8 (95% UI 94.9 to 114.4) deaths per 100,
000 from 1990 to 2017. Comparing to other countries
with similar development stage, such as other countries
from the BRICS group (Brazil, Russia, India, China, and
South Africa), Brazil has reduced the all-cause deaths at-
tributed to HSBP from 2nd to the 5th and least position
of the group from 1990 to 2017, although the rate of
deaths attributed to HSBP in the country are still higher
than other countries with universal healthcare, such as
Canada and England, shown for comparison (Fig. 4).
Table 2 shows the all age deaths and DALYs, in 1990
and 2017, and percent change of deaths and age-
standardized death rates, DALYs, and age-standardized
DALY rates between 1990 and 2017 attributable to high
blood pressure in Brazil and its FUs.
Causes of deaths and DALYs attributable to HSBP
Regarding the leading causes of death attributable to
HSBP, ischemic heart disease is in the 1st position,
followed by stroke (Additional file 2). While the deaths
and DALY due to the main causes of death attributable
to HSBP are decreasing, deaths due to peripheral artery
disease, atrial fibrillation, and aortic aneurysm are rising.
Figure 5 shows that they are similar across federal units.
Hypertensive heart disease and chronic kidney disease
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alternate in the 3rd and 4th position depending on the
federal unit.
Additional file 2 demonstrates all age deaths and DALYs
in 1990 and 2017 and percent change of deaths and age-
standardized death rates, DALYs, and age-standardized
DALY attributable to HSBP, for cardiovascular diseases,
for both sexes and stratified by sex, in Brazil. Figure 6
demonstrates the main causes of deaths and DALY attrib-
utable to HSBP across Brazilian federal units.
Drivers of change in mortality and morbidity attributed
to HSBP
Figure 7 reveals that the rise in deaths and DALY attrib-
utable to HSBP in Brazil was mainly due to population
aging, particularly among women, followed by popula-
tion growth. Changes due to risk exposure played a
more important role in males. Changes in unmeasured
factors (“not included in the analysis”)—including health
care access and quality—contributed decreasing burden,
Fig. 1 Trends in prevalence of high systolic blood pressure in Brazil for men, women, and both sexes for individuals with ≥ 25 years old, 1990–
2017. a Age-standardized prevalence. b Total number
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but were offset by increases due to the other factors
(population aging, growth, and risk exposure) (Fig. 7).
Correlation of death and DALY rates attributable to HSBP
to SDI
Figure 8a, b reveals that the reduction in the all-cause
age-standardized death rates attributable to HSBP is het-
erogeneous across federal units. For example, in Ceará,
the death rate reduced from 97.3 (95% UI 83.6 to 112.0)
per 100,000 in 1990 to 81.3 (95% UI 71.7 to 90.5) per
100,000 in 2017 (16.5% [95% UI 8.9 to 23.3%] decrease),
while in Espírito Santo the change was from 219.7 (95%
UI 192.5 to 245.8) per 100,000 in 1990 to 99.8 (95% UI
90.4 to 109.2) per 100,000 in 2017 (54.6% [95% UI 51.9
to 57.1%] decrease). Figure 8a demonstrates the
correlation between age-standardized death rates attrib-
utable to HSBP and the 2017 SDI. We found a moderate
positive correlation (r = 0.61) in 1990 that was not main-
tained in 2017 (r = − 0.08). Figure 8b shows that the per-
cent change in death rates attributable to HSBP between
1990 and 2017 was strongly and negatively correlated to
the SDI in 2017 (r = − 0.77).
Regarding age-standardized DALY rates attributable to
HSBP, a similar pattern was observed. The moderate
positive correlation found between it and SDI (r = 0.51)
in 1990 was also not maintained in 2017 and became
negative (r = − 0.22) (Fig. 9a), and the percent change in
DALY rates attributable to HSBP between 1990 and
2017 was negatively correlated to the SDI (r = − 0.75)
(Fig. 9b).
Fig. 2 Leading 12 main risk factors for all-causes of death (a) and DALY (b) in Brazil, for both sexes, in 1990 and 2017
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Discussion
HTN is a risk factor for CVD, especially for cerebrovas-
cular diseases, ischemic heart disease, and chronic kid-
ney disease, and its recognition and control should be
emphasized, in order to reduce the burden of its associ-
ated conditions. In our analysis, from 1990 to 2017,
there was an annual (0.4%) increase—with an almost
stable behavior in more recent years—in the age-
standardized prevalence of HSBP, currently the leading
risk factor for death in Brazil. Although the age-
standardized death and DALY rates due to HSBP are de-
clining in Brazil, possibly as a result of successful health
policies, the total number of deaths and DALY are in-
creasing mainly due to population aging. Moreover, the
reduction in age-standardized death and DALY rates are
heterogeneous across FU, being more pronounced in the
more developed FU.
Several factors, including sociodemographic, ethnical,
cultural, dietary, and behavioral issues, may account for
the differences in the burden of HSBP between
Fig. 3 Attributable risk of 17 main risk factors for all-causes of death in Brazil, stratified by sex, in 2017
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populations and also for the trends over decades. Global
prevalence estimates may also vary according to the
methodology applied. The pooled age-standardized
prevalence of HSBP or high DBP in 200 countries was
estimated at 24.1% (95% UI 21.4 to 27.1%) in males and
20.1% (95% UI 17.8 to 22.5%) in females in 2015, with
the authors underscoring the decline observed in Latin
America between the 1970s and 2015, although Brazil
was not specifically mentioned [19]. In the GBD study,
involving 195 countries, the estimated global prevalence
of HSBP was 17.1% in 2017 [9, 11].
Several studies have been conducted on the prevalence
of HTN in Brazilians cities and regions in the last de-
cades, although there is substantial variability of defini-
tions and methodology [1, 10]. Concerning country-wide
studies, the Brazilian Health Ministry has been conduct-
ing, since 2006, a yearly telephonic survey in FU capitals
for chronic diseases and risk factors, the VIGITEL, with
a question about medical diagnosis of hypertension [20,
21]. More recently, in 2013, direct blood pressure mea-
surements, as well as the information about the use of
anti-hypertensive drugs, were incorporated [3]. The
addition of these data to GBD was crucial, as it brings
more realistic information regarding the profile of the
population with HTN. The prevalence of HSBP by GBD
estimates in Brazil, however, cannot be directly com-
pared to previous studies, considering methodological
particularities of the GBD model, in which prevalence is
derived from a continuous distribution of systolic blood
pressure (with a ≥ 140mmHg threshold in this analysis),
and patients with isolated diastolic HTN or those con-
trolled by antihypertensives are not included [9]. This
concern is even more compelling in regions with moder-
ate to good access to medications, where patients under
treatment with SBP levels below 140mmHg will not
meet the cutoff derived from the GBD continuous esti-
mation of systolic BP. Most previous population-based
studies [1, 8, 10] used as the diagnostic criteria the pres-
ence of blood pressure (BP) ≥ 140/90 mmHg or the use
of BP lowering medication, which necessarily led to a
higher prevalence than observed in GBD. Indeed, a
meta-analysis from 2012 showed a mean prevalence
of HTN of 28.7% (26.2–31.4%) for decade of 2000s
[22], while the National Health Survey 2013 (adults >
18 years old) showed a general prevalence of 32.3%
considering direct measurement and/or reported use
of medication, contrasting with 21.4% for self-
reporting and 22.8% for measured HTN [3]. For the
burden estimates, the above concern is not applied,
because HSBP was considered as exposure above a
TMREL of 110–115 mmHg. However, for the purpose
of estimating disease burden attributable to HSBP, the
GBD method of estimating the full distribution of
SBP regardless of medication use seems to be the
best approach, as a continuous exposure measure
takes into account the nuance of different risks for
the different levels of BP.
Analyzing our results stratified by sex, it should be
noted that the prevalence was overall higher among men
during the study period, following a classical trend of
Fig. 4 Trends in all causes of deaths attributable to high systolic blood pressure in Brazil, Russia, India, China, and South Africa (BRICS), Canada,
and England, both sexes and age standardized, 1990–2017
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HTN [13], despite the growing similarities of health be-
haviors between sexes in the past decades [23]. Besides
biological determinants, such as estrogen protection,
several other complex cultural, environmental, behav-
ioral, and healthcare access factors may be implicated in
this difference by sex. Higher prevalence of HSBP in
men differs from the HTN prevalence estimated by self-
reported population surveys [21] which tend to overesti-
mate prevalence in women, whom are generally more
adherent to medical services.
The small percent increase in age-standardized preva-
lence observed in Brazil—especially in men—was rela-
tively homogeneous across the FUs. Of note, only in Rio
Grande do Sul and Santa Catarina, there was no vari-
ation or even a slight reduction trend in this period,
considering the UIs. In the VIGITEL telephone survey,
the prevalence of self-reported medical diagnosis of
HTN did not change from 2006 to 2017 [20]—but a
non-significant increasing trend in the past years was
observed—while a previous meta-analysis of population-
Fig. 5 Main causes of deaths (a) and DALYs (b) attributable to high systolic blood pressure, both sexes, Brazilian federal units, 2017
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based studies showed a trend toward decreasing preva-
lence from 1987 to 2007 [8]. Considering the limitation
of all sources of data for evaluating this discordance,
only a new National Health Survey, planned to be con-
ducted in 2019, will be able to give a definite response
for this question. However, other related risk factors,
such as obesity [24] and diabetes [25], have already in-
creased in prevalence during the same period, suggesting
there is room for health promotion and prevention
strategies that could lead to a better control of cardio-
vascular risk factors in Brazil. Also, considering the GBD
methodology, HSBP can be understood as undetected or
inadequately treated HTN, and the stable-to-growing
trend observed in our analysis may be mainly linked to
unsuccessful treatment. In this scenario, greater access
to home measurement and better efficacy of self-
management programs—including new technology for
remote medical advice—may improve BP control.
Fig. 6 Age-standardized causes of a deaths and b DALYs attributable to high systolic blood pressure in Brazil and its Federal Units in 2017, both
sexes, for men and women
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Despite the observed slight growth of HSBP preva-
lence, the trends in the burden attributable to HSBP in
Brazil, with decreasing age-standardized rates, suggest
that efficient health policies for CVD control were im-
plemented in the period. The increase in total numbers
of deaths and DALY attributable to HSBP depict the ef-
fect of population aging and growth in the country. To
analyze the drivers of the abovementioned trends is es-
sential for health policy planning [26]. The relative con-
tributions of population aging reflect life expectancy at
birth that increased continuously from 1950 to 2017, to
72 years for men and 79 years for women. In Brazil, this
was mainly due to the decline in under-5 mortality, with
a still high mortality among young adult men driven by
interpersonal violence [27]. The relatively small change
due to risk exposure observed predominately in men
could be attributed to the combined effect of birth co-
horts’ improvements and treatment of cardiovascular
and cardiometabolic diseases, which results in the de-
crease of CVD and increase in IHD [26]. This can be
Fig. 7 Percent change in deaths (a) and DALYs (b) attributable to high systolic blood pressure in Brazil, 1990–2016, due to population growth,
population aging, trends in exposure included in GBD 2016, and all other (risk-deleted or residual) factors
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also interpreted as a tradeoff between worsening deter-
minants of HTN—especially age—versus better health-
care. Conversely, the negative trend of “other causes”
(not included in the analysis) is debatable and may also
reflect healthcare and other unmeasured factors—as
population awareness, etc. —or be a result of improving
certainty around measurement in more recent years. A
scenario mainly driven by the rapid change in age com-
position urges health systems to develop long-term ac-
tion plans for improving primary prevention and
sustainable patient-centered educational programs for
healthy aging.
In comparison to other BRICS countries, the mortality
rate per 100,000 inhabitants attributable to HSBP be-
tween 1990 and 2017 decreased 45% in Brazil and 24%
in Russia, while it practically did not change in the other
countries—with even an increasing trend in South Af-
rica—over the period. This finding also suggests the rela-
tive efficiency of the large-scale health policies
implemented in the country for HTN control, such as
established follow-up protocols and multidisciplinary ap-
proach for HTN care in the primary health setting, along
with free access to antihypertensives [6, 8]. However,
among other countries with universal access to health
Fig. 8 Correlation between age-standardized death rates attributable to high systolic blood pressure and the 2017 sociodemographic index (SDI)
in 1990 and 2017 for both sexes, in Brazilian federal units (a) and percent change in death rates attributable to HSBP between 1990 and 2017 (b)
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such as Canada and England, we find attributable mor-
tality rates to be about half those observed in Brazil in
2017. Notably, England and Brazil had comparable at-
tributable mortality rates in 1990, indicating that even
greater prevention of burden due to HTN may be pos-
sible in Brazil. The 2011 Brazilian plan to confront the
non-communicable diseases (NCDs) [28], consonant
with the World Health Organization (WHO) Action
Plan [29] and the United Nations 2030 Sustainable De-
velopment Goals [30], emphasizes, among other ap-
proaches aiming a 25% reduction of NCD-associated
mortality by 2025, the control of HTN and many of its
determinants. However, considering the stable trend of
prevalence and the absolute burden, the results are still
suboptimal. One of the reasons for this may be that
greater healthcare, medication access, and public policies
to prevent CVD are being counterbalanced by unsuc-
cessful approaches to control the determinants of HTN,
such as overweight, alcohol intake, and physical
inactivity.
It is interesting that prevalence varied considerably
among FUs, which may be partially explained by differ-
ent stages of the epidemiological transition across the
country. Age-standardized death and DALY rates were
Fig. 9 Correlation between age-standardized DALY rates attributable to high systolic blood pressure and sociodemographic index (SDI) in 1990
and 2017 for both sexes, in Brazilian federal units (a) and percent change in DALY rates attributable to HSBP between 1990 and 2017 (b)
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higher in FUs with higher SDI in 1990, and the greatest
reduction in burden was observed in these locations. In
fact, considering the SDI as a proxy for socioeconomic
development, the strong positive correlation observed in
1990 contrasts with the absence of significant correlation
in 2017, revealing that greater sociodemographic devel-
opment was associated with the reduction in the burden
attributable to HSBP in Brazil. This is supported by the
strong negative correlation between the percent changes
in death and DALY rates attributable to HSBP between
1990 and 2017 and the 2017 SDI. The relation of socio-
economic development and disease burden in Brazil has
already been observed: significantly negative correlation
coefficients between the municipal HDI (an index that
similarly reflects local development) in 2000 and 2013
and mortality rates for CVD and hypertensive diseases
in the state of Rio de Janeiro have been reported [31].
Higher socioeconomic development may be associated
with greater awareness about the effects of HTN and
better access to healthcare, such as public and private
programs related to education, diet, behaviors, and risk
factors’ control over the period evaluated. Moreover, the
improvement in socioeconomic conditions of the Brazil-
ian FUs—while in 1990 the lowest SDI was 0.31 in
Maranhão, in 2017 it was 0.51—and the consequent re-
duction in socioeconomic gap between FU in Brazil
from 1990 and 2017 may have contributed to reduce the
magnitude of the statistical correlation with disease bur-
den. According to the United Nations Organizations def-
inition, about 50% of the Brazilian FU reached a high
Human Development Index (HDI) (≥ 0.7) by the 2010
decade, explaining the decreasing power of this associ-
ation [32] and highlighting the health burden posed by
socioeconomic disparities. In Brazilian case, the reduc-
tion of the HTN burden clearly followed social develop-
ment. These observations follow a global trend of linear
increase of HSBP burden and SDI in places with low
baseline SDI [9], hypothetically as a result of lifestyle/be-
havioral changes increasing metabolic risk factors as the
country develops. A drop of HSBP is then observed at
high SDIs, when development is enough to allow for ad-
equate BP control.
HSBP accounted for the highest proportion of deaths
in 2017 in both sexes, followed by dietary risks and in-
creased body mass index in women, with tobacco con-
sumption prevailing over dietary risks for men.
Regarding the leading causes of DALY, the overall pat-
tern substantially changed as a reflex of the epidemio-
logical transition, from child and maternal malnutrition
in 1990 (with HSPB in the 4th position) to tobacco in
2017, followed by HSBP. These findings differ from
those reported in 2015, when dietary risks—improved by
successful strategies focused on diet and other health be-
haviors—were the main cause of DALYs [33]. On the
other hand, a recent study observed a decrease in the
smoking reduction trend, which varied from − 23.4% in
the years 2010–2014 to − 2.9% in the period 2015–2017,
even with an increase in prevalence in the population
with ≥ 9 years of schooling—an alarming trend, consid-
ering the successful anti-tobacco initiatives in the past
decades. The authors point to one of the possible deter-
minants: the fiscal austerity and the economic crisis that
Brazil is currently experiencing [2], limiting the expan-
sion of health education programs. These data point to-
ward the need for individualized approaches for men
and women in prevention and awareness programs, re-
inforcing—as examples—tobacco cessation for men,
while focusing on dietary habits and obesity for women.
HTN, for instance, must remain as a top priority for
policy-making.
Ischemic heart disease and stroke remained as the first
and second leading causes of age-standardized deaths
and DALYs attributable to HSBP respectively, in both
sexes, in 2017, in Brazil and its FU [34]. This suggests a
more chronic end-organ damage profile, also deeply as-
sociated with other common risk factors such as to-
bacco, diabetes, and cardiometabolic factors [35]. Similar
to aging, the growing impact of such factors—affecting
ischemic diseases—can be understood as a product of
the late epidemiological transition. Also, better access to
healthcare seems to result in a more acute reduction of
morbidity and mortality associated with kidney disease
and hypertensive heart disease [13]. For the reduction of
this burden, there has been much debate about adequate
targets for blood pressure control and their clinical feasi-
bility, as meta-analyses and primary data strongly sug-
gest cardiovascular mortality benefits for a target SBP <
120 mm Hg [13, 36, 37]. These observations support the
assumption that adequate SBP control modifies the asso-
ciated mortality in a progressive fashion, although the
precise subpopulations that benefit from intensive con-
trol and the optimal targets remain unclear [13]. The
new BP target recommendations [35] have not yet been
incorporated by Brazilian guidelines [4]. However, the
ability to control determinants of HTN (e.g., diet, salt
and alcohol intake, obesity) in the population may be
more important than the unclear benefits of intensified
BP targets.
Thus, cardiovascular health overall improved substan-
tially in Brazil from 1990 to 2017, with important differ-
ences across the geographical regions of the country
[38]. This reduction was more pronounced in the states
in the southern and southeastern regions possibly being
influenced by socioeconomic development [39, 40]. Our
findings from the GBD 2017 estimates reinforce these
observations, pointing toward the need for a broad dis-
cussion about the directions of cardiovascular care in
Brazil in the coming years. More than access to medical
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appointments, adequate long-term HTN control is
highly dependent on population education to improve
awareness and health promotion through a multidiscip-
linary approach, as well as improvement of the quality of
care [6]. In part, this is the scope of the Family Health
program that has been developed in the Brazilian pri-
mary care system since the 1990s, which should be fur-
ther promoted [8]. Although it is necessary to provide
universal access and high-quality healthcare, it is
mandatory to also act on social determinants of health
to sustainably reduce the burden of CVD [41].
Limitations and strengths
The limitations of the GBD study models have been pre-
viously detailed [9]. Despite the improvement in avail-
ability of primary data in Brazil from 1990 to 2017, the
publications are still heterogeneous, and data are still
scarce for some regions, especially the less resourced
ones as the North and Northeast. However, the imple-
mentation of health surveys in the country with mea-
sured blood pressures, such as the “National Health
Survey” (Pesquisa Nacional de Saúde—PNS) are recently
improving the knowledge of the epidemiological profile
of the population [3]. Furthermore, 140 mmHg was the
threshold for prevalence estimates, despite the changes
in the 2017 American Heart Association/American Col-
lege of Cardiology Guidelines driven by robust data [35,
36]. The past threshold, however, remains acceptable for
a considerable proportion of the population. Also, of
note, controlled HTN and isolated DBP were not con-
sidered for the estimates, although the latter is uncom-
mon and unlikely to explain differences in prevalence.
Although it is recognized that systolic values have stron-
ger associations with health outcomes, these may also be
sources of bias [13] accounting, along with abovemen-
tioned particularities of the GBD model, for the consid-
erable lower prevalence of HSBP in comparison with
primary HTN data. This precludes the direct compari-
son with other studies that used definitions that consid-
ered DBP and treated HTN, as mentioned, as different
conditions are being measured. Finally, disability weights
were not country-specific and may be prone to some im-
precision, although some data has shown that they are
relatively stable across different populations [14].
Despite the above limitations, GBD is a robust and
broad epidemiological initiative, for estimating the mor-
bidity and mortality due to HSBP in the entire Brazilian
territory, especially in regions where primary data is
scarce, where temporal-spatial complex models provide
reliable estimates, previously unavailable [9, 13]. The
lack of precision of some aspects of the subnational
models in Brazil—requiring a close evaluation of uncer-
tainty intervals provided by GBD—does not affect the
main findings and the contribution of this approach to
evaluate the health impact of HSBP and help develop
policies for its confrontation. The main strength of this
study is to be, at the best of our knowledge, the most
comprehensive countrywide data demonstrating the sig-
nificant reduction of age-standardized death and DALY
rates attributable to HSBP in Brazil, but also the main-
tenance of HSBP as the main risk factor for death in the
country.
Conclusion
The age-standardized death rates attributable to HSBP
are decreasing in Brazil, probably revealing the results of
successful public health policies for CVD secondary pre-
vention and control, markedly public campaigns and the
availability of drug therapy in the public health system.
However, prevalence data still shows a trend of increase
that deserves to be confirmed by a new National Health
Survey. Moreover, HSBP continues to be the main risk
factor for death in the country and an increase in the
total number of diseases attributable to HSBP in the
near future is foreseen, mainly due to population aging
and growth. These findings, along with the correlation
between high SDI and the reduction in the burden at-
tributable to HSBP, suggest that health policies must
focus on healthy aging and the underserved population,
emphasizing specific strategies for HTN screening, treat-
ment, and adherence. Sensitization at different levels,
from health policy-makers to civil society organizations,
is crucial for the development of contemporary strategies
to confront HSBP in Brazil in order to diminish the bur-
den of health loss due to HSBP in the next decades.
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